Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CIRCUMVENTION' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 114 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Uchiyama-Kokubu, N; Watanabe, T; Cohen, D
      Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15

      JAPANESE JOURNAL OF CANCER RESEARCH
    2. Rux, JJ; Burnett, RM
      Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon

      MOLECULAR THERAPY
    3. Manzotti, C; Pratesi, G; Menta, E; Di Domenico, R; Cavalletti, E; Fiebig, HH; Kelland, LR; Farrell, N; Polizzi, D; Supino, R; Pezzoni, G; Zunino, F
      BBR 3464: A novel triplatinum complex, exhibiting a preclinical profile ofantitumor efficacy different from cisplatin

      CLINICAL CANCER RESEARCH
    4. Stallwood, Y; Fisher, KD; Gallimore, PH; Mautner, V
      Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients

      GENE THERAPY
    5. Holford, J; Beale, PJ; Boxall, FE; Sharp, SY; Kelland, LR
      Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines

      EUROPEAN JOURNAL OF CANCER
    6. Berman, DA
      Balanced and purposeful departures: Fixing a jurisprudence that underminesthe federal sentencing guidelines

      NOTRE DAME LAW REVIEW
    7. Tidefelt, U; Liliemark, J; Gruber, A; Liliemark, E; Sundman-Engberg, B; Juliusson, G; Stenke, L; Elmhorn-Rosenborg, A; Mollgard, L; Lehman, S; Xu, D; Covelli, A; Gustavsson, B; Paul, C
      P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with p-glycoprotein-positive acute myeloid leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    8. Merlin, JL; Bour-Dill, C; Marchal, S; Ramacci, C; Poullain, MG; Giroux, B
      Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in golgi vesicles

      CYTOMETRY
    9. Fukushima, T; Yamashita, T; Takemura, H; Suto, H; Kishi, S; Urasaki, Y; Ueda, T
      Effect of PSC 833 on the cytotoxicity and pharmacodynamics of mitoxantronein multidrug-resistant K562 cells

      LEUKEMIA RESEARCH
    10. Eisner, T; Eisner, M
      Defensive use of a fecal thatch by a beetle larva (Hemisphaerota cyanea)

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    11. Beale, PJ; Rogers, P; Boxall, F; Sharp, SY; Kelland, LR
      BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma

      BRITISH JOURNAL OF CANCER
    12. Kelland, LR; Sharp, SY; O'Neill, CF; Raynaud, FI; Beale, PJ; Judson, IR
      Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance

      JOURNAL OF INORGANIC BIOCHEMISTRY
    13. Roovers, DJ; van Vliet, M; Bloem, AC; Lokhorst, HM
      Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines

      LEUKEMIA RESEARCH
    14. Schwartz, DR; Homanics, GE; Hoyt, DG; Klein, E; Abernethy, J; Lazo, JS
      The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    15. Lowe, G; Droz, AS; Vilaivan, T; Weaver, GW; Park, JJ; Pratt, JM; Tweedale, L; Kelland, LR
      Cytotoxicity of 2,2 ': 6 ',2 ''-terpyridineplatinum(II) complexes against human ovarian carcinoma

      JOURNAL OF MEDICINAL CHEMISTRY
    16. Berger, D; Citarella, R; Dutia, M; Greenberger, L; Hallett, W; Paul, R; Powell, D
      Novel multidrug resistance reversal agents

      JOURNAL OF MEDICINAL CHEMISTRY
    17. Mistry, P; Plumb, J; Eccles, S; Watson, S; Dale, I; Ryder, H; Box, G; Charlton, P; Templeton, D; Bevan, PB
      In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance

      BRITISH JOURNAL OF CANCER
    18. Tanabe, H; Tasaka, S; Ohmori, H; Gomi, N; Sasaki, Y; Machida, T; Iino, M; Kiue, A; Naito, S; Kuwano, M
      Newly synthesized dihydropyridine derivatives as modulators of P-glycoprotein-mediated multidrug resistance

      BIOORGANIC & MEDICINAL CHEMISTRY
    19. DUFFY CP; ELLIOTT CJ; OCONNOR RA; HEENAN MM; COYLE S; CLEARY IM; KAVANAGH K; VERHAEGEN S; OLOUGHLIN CM; NICAMHLAOIBH R; CLYNES M
      ENHANCEMENT OF CHEMOTHERAPEUTIC DRUG TOXICITY TO HUMAN TUMOR-CELLS IN-VITRO BY A SUBSET OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS (NSAIDS)

      European journal of cancer
    20. BERTOUNESQUE E; MILLAL F; MERESSE P; MONNERET C
      SYNTHESIS OF A HIGHLY FUNCTIONALIZED GAMMA-LACTONE AS A PRECURSOR OF 9-PENTYL ANTHRACYCLINES

      Tetrahedron : asymmetry
    21. PEREGO P; ROMANELLI S; CARENINI N; MAGNANI I; LEONE R; BONETTI A; PAOLICCHI A; ZUNINO F
      OVARIAN-CANCER CISPLATIN-RESISTANT CELL-LINES - MULTIPLE CHANGES INCLUDING COLLATERAL SENSITIVITY TO TAXOL

      Annals of oncology
    22. FENART L; BUEESCHERRER V; DESCAMPS L; DUHEM C; POULLAIN MG; CECCHELLI R; DEHOUCK MP
      INHIBITION OF P-GLYCOPROTEIN - RAPID ASSESSMENT OF ITS IMPLICATION INBLOOD-BRAIN-BARRIER INTEGRITY AND DRUG TRANSPORT TO THE BRAIN BY AN IN-VITRO MODEL OF THE BLOOD-BRAIN-BARRIER

      Pharmaceutical research
    23. HOLFORD J; RAYNAUD F; MURRER BA; GRIMALDI K; HARTLEY JA; ABRAMS M; KELLAND LR
      CHEMICAL, BIOCHEMICAL AND PHARMACOLOGICAL ACTIVITY OF THE NOVEL STERICALLY HINDERED PLATINUM COORDINATION COMPLEX, CIS-[AMMINEDICHLORO(2-METHYLPYRIDINE)] PLATINUM(II) (AMD473)

      Anti-cancer drug design
    24. FERNANDEZ M; HEREDIA ML; DELACUESTA E; AVENDANO C
      VILSMEIER AND MANNICH REACTIONS ON (4S)-N-2-SUBSTITUTED 4-DIHYDRO-1H-PYRAZINO[2,1-B]QUINAZOLINE-3,6-DIONES

      Tetrahedron
    25. GALL JGD; CRYSTAL RG; FALCKPEDERSEN E
      CONSTRUCTION AND CHARACTERIZATION OF HEXON-CHIMERIC ADENOVIRUSES - SPECIFICATION OF ADENOVIRUS SEROTYPE

      Journal of virology (Print)
    26. DALE IL; TUFFLEY W; CALLAGHAN R; HOLMES JA; MARTIN K; LUSCOMBE M; MISTRY P; RYDER H; STEWART AJ; CHARLTON P; TWENTYMAN PR; BEVAN P
      REVERSAL OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE BY XR9051, ANOVEL DIKETOPIPERAZINE DERIVATIVE

      British Journal of Cancer
    27. HOLFORD J; SHARP SY; MURRER BA; ABRAMS M; KELLAND LR
      IN-VITRO CIRCUMVENTION OF CISPLATIN RESISTANCE BY THE NOVEL STERICALLY HINDERED PLATINUM COMPLEX AMD473

      British Journal of Cancer
    28. BICHAT F; SOLISRECENDEZ G; POULLAIN MG; POUPON MF; KHAYAT D; BASTIAN G
      S9788 MODULATION OF P-GLYCOPROTEIN-RELATED AND MULTIDRUG-RELATED PROTEIN-MEDIATED MULTIDRUG-RESISTANCE BY SERVIER-9788 IN DOXORUBICIN-RESISTANT MCF7 CELLS

      Biochemical pharmacology
    29. YANG JM; SULLIVAN GF; MAKHEY DB; LAVOIE EJ; HAIT WN
      INHIBITORY EFFECT OF ALKYLATING MODULATORS ON THE FUNCTION OF P-GLYCOPROTEIN

      Oncology research
    30. NARASAKI F; OKA M; FUKUDA M; NAKANO R; IKEDA K; TAKATANI H; TERASHI K; SODA H; YANO O; NAKAMURA T; DOYLE LA; TSURUO T; KOHNO S
      A NOVEL QUINOLINE DERIVATIVE, MS-209, OVERCOMES DRUG-RESISTANCE OF HUMAN LUNG-CANCER CELLS EXPRESSING THE MULTIDRUG RESISTANCE-ASSOCIATE PROTEIN (MRP) GENE

      Cancer chemotherapy and pharmacology
    31. COVELLI A
      SDZ-PSC-833 - A NEW MULTIDRUG-RESISTANCE MODULATOR

      Tumori
    32. EHRLICH PH; MOUSTAFA ZA; ARCHINALMATTHEIS AE; NEWMAN MJ; BAIR KW; COHEN D
      THE REVERSAL OF MULTIDRUG-RESISTANCE IN MULTICELLULAR TUMOR SPHEROIDSBY SDZ PSC-833

      Anticancer research
    33. HOLMES FA; LOPEZ A; MAVLIGIT G; FRASCHINI G; FRYE D; HORTOBAGYI GN
      SECONDARY DRUG-RESISTANCE IN BREAST-CANCER - FAILURE TO REVERSE WITH ORAL NIFEDIPINE

      International journal of cancer
    34. PUNT CJA; VOEST EE; TUENI E; VANOOSTEROM AT; BACKX A; DEMULDER PHM; HECQUET B; LUCAS C; GERARD B; BLEIBERG H
      PHASE IB STUDY OF DOXORUBICIN IN COMBINATION WITH THE MULTIDRUG-RESISTANCE REVERSING AGENT S9788 IN ADVANCED COLORECTAL AND RENAL-CELL CANCER

      British Journal of Cancer
    35. WATANABE T; NAITO M; KOKUBU N; TSURUO T
      REGRESSION OF ESTABLISHED TUMORS EXPRESSING P-GLYCOPROTEIN BY COMBINATIONS OF ADRIAMYCIN, CYCLOSPORINE DERIVATIVES, AND MRK-16 ANTIBODIES

      Journal of the National Cancer Institute
    36. FLANDINA C; FLUGY A; BORSELLINO N; DALESSANDRO N
      DEVELOPMENT AND PARTIAL CHARACTERIZATION OF A HUMAN T-LYMPHOBLASTIC LEUKEMIC (CCRF-CEM) CELL-LINE RESISTANT TO ETOPOSIDE - ANALYSIS OF POSSIBLE CIRCUMVENTING APPROACHES

      Journal of chemotherapy
    37. TIMCHEVA CV; TODOROV DK
      DOES VERAPAMIL HELP OVERCOME MULTIDRUG-RESISTANCE IN TUMOR-CELL LINESAND CANCER-PATIENTS

      Journal of chemotherapy
    38. ALIGIANNIS N; POULI N; MARAKOS P; SKALTSOUNIS AL; LEONCE S; PIERRE A; ATASSI G
      SYNTHESIS AND BIOLOGICAL-ACTIVITY OF 4'-AZIDO-3'-CHLORO-3'-DEAMINO-4'-DEOXYDAUNORUBICIN AND CETAMIDO-3'-CHLORO-3'-DEAMINO-4'-DEOXYDAUNORUBICIN

      Bioorganic & medicinal chemistry letters
    39. WATANABE T; NAKAYAMA Y; NAITO M; OHHARA T; ITOH Y; TSURUO T
      CREMOPHOR EL REVERSED MULTIDRUG-RESISTANCE IN-VITRO BUT NOT IN TUMOR-BEARING MOUSE MODELS

      Anti-cancer drugs
    40. WATANABE T; NAITO M; OHHARA T; ITOH Y; COHEN D; TSURUO T
      MODULATION OF MULTIDRUG-RESISTANCE BY SDZ PSC-833 IN LEUKEMIC AND SOLID-TUMOR-BEARING MOUSE MODELS

      Japanese journal of cancer research
    41. SONNEVELD P; MARIE JP; HUISMAN C; VEKHOFF A; SCHOESTER M; FAUSSAT AM; VANKAPEL J; GROENEWEGEN A; CHARNICK S; ZITTOUN R; LOWENBERG B
      REVERSAL OF MULTIDRUG-RESISTANCE BY SDZ PSC-833, COMBINED WITH VAD (VINCRISTINE, DOXORUBICIN, DEXAMETHASONE) IN REFRACTORY MULTIPLE-MYELOMA- A PHASE-I STUDY

      Leukemia
    42. BOOTE DJ; DENNIS IF; TWENTYMAN PR; OSBORNE RJ; LABURTE C; HENSEL S; SMYTH JF; BRAMPTON MH; BLEEHEN NM
      PHASE-I STUDY OF ETOPOSIDE WITH SDZ PSC 833 AS A MODULATOR OF MULTIDRUG-RESISTANCE IN PATIENTS WITH CANCER

      Journal of clinical oncology
    43. MICHIELI M; DAMIANI D; MICHELUTTI A; MELLI C; ERMACORA A; GEROMIN A; FANIN R; RUSSO D; BACCARANI M
      OVERCOMING PGP-RELATED MULTIDRUG-RESISTANCE - THE CYCLOSPORINE DERIVATIVE SDZ PSC-833 CAN ABOLISH THE RESISTANCE TO METHOXY-MORPHOLYNIL-DOXORUBICIN

      Haematologica
    44. OHISHI I; MORINAGA Y; OHSUMI K; NAKAGAWA R; SUGA E; TSUJI T; AKIYAMA Y; TSURUO T
      POTENTIATION OF ANTITUMOR AND ANTIMETASTATIC ACTIVITIES OF ADRIAMYCINBY A NOVEL N-ALKYLATED DIHYDROPYRIDINE, AC394, AND ITS ENANTIOMERS INCOLON CANCER-BEARING MICE

      Cancer chemotherapy and pharmacology
    45. NOOTER K; STOTER G
      MOLECULAR MECHANISMS OF MULTIDRUG-RESISTANCE IN CANCER-CHEMOTHERAPY

      Pathology research and practice
    46. QUESADA AR; BARBACID MM; MIRA E; ARACIL M; MARQUEZ G
      CHEMOSENSITIZATION AND DRUG ACCUMULATION ASSAYS AS COMPLEMENTARY METHODS FOR THE SCREENING OF MULTIDRUG-RESISTANCE REVERSAL AGENTS

      Cancer letters
    47. JOLY P; LALLEMAND A; OUMHAMED Z; TRENTESAUX C; IDOINE O; DESPLACES A
      EFFECTS OF VERAPAMIL AND S9788 ON MDR-1 MESSENGER-RNA EXPRESSION STUDIED BY IN-SITU HYBRIDIZATION

      Anticancer research
    48. DAVEY MW; HARGRAVE RM; DAVEY RA
      COMPARISON OF DRUG ACCUMULATION IN P-GLYCOPROTEIN-EXPRESSING AND MRP-EXPRESSING HUMAN LEUKEMIA-CELLS

      Leukemia research
    49. MANKHETKORN S; DUBRU F; HESSCHENBROUCK J; FIALLO M; GARNIERSUILLEROT A
      RELATION AMONG THE RESISTANCE FACTOR, KINETICS OF UPTAKE, AND KINETICS OF THE P-GLYCOPROTEIN-MEDIATED EFFLUX OF DOXORUBICIN, DAUNORUBICIN, 8-(S)-FLUOROIDARUBICIN, AND IDARUBICIN IN MULTIDRUG-RESISTANT K562 CELLS

      Molecular pharmacology
    50. TAKESHITA H; GEBHARDT MC; SPRINGFIELD DS; KUSUZAKI K; MANKIN HJ
      EXPERIMENTAL-MODELS FOR THE STUDY OF DRUG-RESISTANCE IN OSTEOSARCOMA - P-GLYCOPROTEIN-POSITIVE, MURINE OSTEOSARCOMA CELL-LINES

      Journal of bone and joint surgery. American volume
    51. DEMMER A; DUNN T; HOOF T; KUBESCH P; TUMMLER B
      COMPETITIVE-INHIBITION OF PHOTOAFFINITY-LABELING OF P-GLYCOPROTEIN BYANTICANCER DRUGS AND MODULATORS INCLUDING S9788

      European journal of pharmacology
    52. DANTZIG AH; SHEPARD RL; CAO J; LAW KL; EHLHARDT WJ; BAUGHMAN TM; BUMOL TF; STARLING JJ
      REVERSAL OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE BY A POTENT CYCLOPROPYLDIBENZOSUBERANE MODULATOR, LY335979

      Cancer research
    53. SHARP SY; ROGERS PM; KELLAND LR
      TRANSPORT OF CISPLATIN AND BIS-ACETATO-AMMINE-DICHLOROCYCLOHEXYL-AMINE PLATINUM(IV) (JM216) IN HUMAN OVARIAN-CARCINOMA CELL-LINES - IDENTIFICATION OF A PLASMA-MEMBRANE PROTEIN ASSOCIATED WITH CISPLATIN RESISTANCE

      Clinical cancer research
    54. PFISTER JR; MAKRA F; MUEHLDORF AV; WU H; NELSON JT; CHEUNG P; BRUNO NA; CASEY SM; ZUTSHI N; SLATE DL
      METHANODIBENZOSUBERYLPIPERAZINES AS POTENT MULTIDRUG-RESISTANCE REVERSAL AGENTS

      Bioorganic & medicinal chemistry letters
    55. BERTRAM J; PALFNER K; KILLIAN M; BRYSCH W; SCHLINGENSIEPEN KH; HIDDEMANN W; KNEBA M
      REVERSAL OF MULTIPLE-DRUG RESISTANCE IN-VITRO BY PHOSPHORATHIOATE OLIGONUCLEOTIDES AND RIBOZYMES

      Anti-cancer drugs
    56. SOUDON J; BERLION M; LUCAS C; HADDAD P; BIZZARI JP; CALVO F
      IN-VITRO ACTIVITY OF S-9788 ON A MULTIDRUG-RESISTANT LEUKEMIC-CELL LINE AND ON NORMAL HEMATOPOIETIC CELLS-REVERSAL OF MULTIDRUG-RESISTANCE BY SERA FROM PHASE-I TREATED PATIENTS

      Cancer chemotherapy and pharmacology
    57. WATANABE T; TSUGE H; OHHARA T; NAITO M; TSURUO T
      COMPARATIVE-STUDY ON REVERSAL EFFICACY OF SDZ PSC-833, CYCLOSPORINE-AAND VERAPAMIL ON MULTIDRUG-RESISTANCE IN-VITRO AND IN-VIVO

      Acta oncologica
    58. OUDARD S; THIOUNN N; COPEL LB; CHAUVENET L; LAURAINE EP; BERNADOU A
      RESISTANCE TO CHEMOTHERAPY IN RENAL-CELL CANCER AND THERAPEUTIC PROSPECTIVES

      Journal d'urologie
    59. SCHWABE K; STEINHEIDER G; LAWEN A; TRABER R; HILDEBRANDT A
      REVERSAL OF MULTIDRUG-RESISTANCE BY NOVEL CYCLOSPORINE-A ANALOGS AND THE CYCLOPEPTIDE SDZ-214-103 BIOSYNTHESIZED IN-VITRO

      Journal of cancer research and clinical oncology
    60. ELZAYAT AAE; IZQUIERDO MA; CLARK GM; VONHOFF DD
      ACTIVITY OF THE MORPHOLINO ANTHRACYCLINE MINO-3'-MORPHOLINO-13-DEOXO-10-HYDROXYCARMINOMYCIN (MX2) AGAINST HUMAN TUMOR COLONY-FORMING-UNITS IN-VITRO

      Investigational new drugs
    61. TESTI R; MATTII L; DISIMONE D; ZACCARO L; MALVALDI G; GRASSI B; PETRINI M
      EVALUATION OF RESISTANCE INDEX OF SEVERAL ANTICANCER AGENTS ON PARENTAL AND RESISTANT P-388 CELL-LINES

      Leukemia research
    62. HERMAN LW; SHARMA V; KRONAUGE JF; BARBARICS E; HERMAN LA; PIWNICAWORMS D
      NOVEL HEXAKIS(ARENEISONITRILE)TECHNETIUM(I) COMPLEXES AS RADIOLIGANDSTARGETED TO THE MULTIDRUG-RESISTANCE P-GLYCOPROTEIN

      Journal of medicinal chemistry
    63. SCHINKEL AH; WAGENAAR E; VANDEEMTER L; MOL CAAM; BORST P
      ABSENCE OF THE MDR1A P-GLYCOPROTEIN IN MICE AFFECTS TISSUE DISTRIBUTION AND PHARMACOKINETICS OF DEXAMETHASONE, DIGOXIN, AND CYCLOSPORINE-A

      The Journal of clinical investigation
    64. NAFZIGER J; AVERLAND G; BERTOUNESQUE E; GAUDEL G; MONNERET C
      SYNTHESIS AND ANTIPROLIFERATIVE EFFECTS OF A 4'-MORPHOLINO-9-METHYL ANTHRACYCLINE

      Journal of antibiotics
    65. DIDIER AD; LOOR F
      DECREASED BIOTOLERABILITY FOR IVERMECTIN AND CYCLOSPORINE-A IN MICE EXPOSED TO POTENT P-GLYCOPROTEIN INHIBITORS

      International journal of cancer
    66. GIANDOMENICO CM; ABRAMS MJ; MURRER BA; VOLLANO JF; RHEINHEIMER MI; WYER SB; BOSSARD GE; HIGGINS JD
      CARBOXYLATION OF KINETICALLY INERT PLATINUM(IV) HYDROXY COMPLEXES - AN ENTREE INTO ORALLY-ACTIVE PLATINUM(IV) ANTITUMOR AGENTS

      Inorganic chemistry
    67. OHSUMI K; OHISHI K; MORINAGA Y; NAKAGAWA R; SUGA Y; SEKIYAMA T; AKIYAMA Y; TSUJI T; TSURUO T
      N-ALKYLATED 1,4-DIHYDROPYRIDINES - NEW AGENTS TO OVERCOME MULTIDRUG-RESISTANCE

      Chemical and Pharmaceutical Bulletin
    68. DALTON WS; CROWLEY JJ; SALMON SS; GROGAN TM; LAUFMAN LR; WEISS GR; BONNET JD
      A PHASE-III RANDOMIZED STUDY OF ORAL VERAPAMIL AS A CHEMOSENSITIZER TO REVERSE DRUG-RESISTANCE IN PATIENTS WITH REFRACTORY MYELOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY

      Cancer
    69. LUDESCHER C; EISTERER W; HILBE W; HOFMANN J; THALER J
      DECREASED POTENCY OF MDR-MODULATORS UNDER SERUM CONDITIONS DETERMINEDBY A FUNCTIONAL ASSAY

      British Journal of Haematology
    70. COWIE FJ; PINKERTON CR; PHILLIPS M; DICK G; JUDSON I; MCCARTHY PT; FLANAGAN RJ
      CONTINUOUS-INFUSION VERAPAMIL WITH ETOPOSIDE IN RELAPSED OR RESISTANTPEDIATRIC CANCERS

      British Journal of Cancer
    71. PIWNICAWORMS D; RAO VV; KRONAUGE JF; CROOP JM
      CHARACTERIZATION OF MULTIDRUG-RESISTANCE P-GLYCOPROTEIN TRANSPORT FUNCTION WITH AN ORGANOTECHNETIUM CATION

      Biochemistry
    72. BORREL MN; FIALLO M; VERESS I; GARNIERSUILLEROT A
      THE EFFECT OF CROWN-ETHERS, TETRAALKYLAMMONIUM SALTS, AND POLYOXYETHYLENE AMPHIPHILES ON PIRARUBICIN INCORPORATION IN K562 RESISTANT CELLS

      Biochemical pharmacology
    73. VILADKAR A; CHITNIS M
      IN-VITRO EFFECTS OF PENTOXIFYLLINE AND DOXORUBICIN ON CELL-SURVIVAL AND DNA-DAMAGE IN SENSITIVE AND MDR-P388 LEUKEMIA-CELLS

      Cancer biotherapy
    74. LEONCE S; PIERRE A; PEREZ V; GUILBAUD N; KRAUSBERTHIER L; GENTON A; LOMBET A; PEGLION JL; ATASSI G
      MULTIDRUG-RESISTANCE CIRCUMVENTION AND INHIBITION OF [H-3] AZIDOPINE PHOTOLABELING OF P-GLYCOPROTEIN BY NEW DIHYDROPYRIDINE DERIVATIVES DISPLAYING A LOW-AFFINITY FOR CALCIUM CHANNELS

      International journal of oncology
    75. JACHEZ B; BOESCH D; EMMER G; LOOR F
      SDZ 280-125 - A CYCLOPEPTOLIDE ENDOWED WITH AN IN-VITRO CYCLOSPORINE A-LIKE PROFILE OF ACTIVITY FOR THE REVERSION OF THE P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE OF TUMOR-CELLS

      Anti-cancer drugs
    76. BARANCIK M; POLEKOVA L; MRAZOVA T; BREIER A; STANKOVICOVA T; SLEZAK J
      REVERSAL EFFECTS OF SEVERAL CA2-ENTRY BLOCKERS, NEUROLEPTICS AND LOCAL-ANESTHETICS ON P-GLYCOPROTEIN-MEDIATED VINCRISTINE RESISTANCE OF L1210()VCR MOUSE LEUKEMIC-CELL LINE/

      Drugs under experimental and clinical research
    77. SHARP SY; MISTRY P; VALENTI MR; BRYANT AP; KELLAND LR
      SELECTIVE POTENTIATION OF PLATINUM DRUG CYTOTOXICITY IN CISPLATIN-SENSITIVE AND CISPLATIN-RESISTANT HUMAN OVARIAN-CARCINOMA CELL-LINES BY AMPHOTERICIN-B

      Cancer chemotherapy and pharmacology
    78. WANG L; YANG CPH; HORWITZ SB; TRAIL PA; CASAZZA AM
      REVERSAL OF THE HUMAN AND MURINE MULTIDRUG-RESISTANCE PHENOTYPE WITH MEGESTROL-ACETATE

      Cancer chemotherapy and pharmacology
    79. HILL BT; HOSKING LK
      DIFFERENTIAL EFFECTIVENESS OF A RANGE OF NOVEL DRUG-RESISTANCE MODULATORS, RELATIVE TO VERAPAMIL, IN INFLUENCING VINBLASTINE OR TENIPOSIDE CYTOTOXICITY IN HUMAN LYMPHOBLASTOID CCRF-CEM SUBLINES EXPRESSING CLASSIC OR ATYPICAL MULTIDRUG-RESISTANCE

      Cancer chemotherapy and pharmacology
    80. KRAUSBERTHIER L; GUILBAUD N; PEGLION JL; LEONCE S; LOMBET A; PIERRE A; ATASSI G
      IN-VIVO REVERSAL OF MULTIDRUG-RESISTANCE BY 2 NEW DIHYDROPYRIDINE DERIVATIVES, S16317 AND S16324

      Acta oncologica
    81. SIDDIK ZH; THAI G; YOSHIDA M; ZHANG YP; KHOKHAR AR
      TETRAVALENT PLATINUM COMPLEXES WITH AMMINE AMINE CARRIER LIGAND CONFIGURATION - CIRCUMVENTION OF PLATINUM RESISTANCE IN-VIVO

      Anti-cancer drug design
    82. DEMETZOS C; SKALTSOUNIS AL; MICHEL S; TILLEQUIN F; KOCH M; ANSTETT M; LEONCE S; PIERRE A; ATASSI G
      SYNTHESIS AND BIOLOGICAL-ACTIVITY OF 3'-DEAMINO-3'-HALOANTHRACYCLINES

      Anti-cancer drug design
    83. SEBILLE S; MORJANI H; POULLAIN MG; MANFAIT M
      EFFECT OF S9788, CYCLOSPORINE-A AND VERAPAMIL ON INTRACELLULAR-DISTRIBUTION OF THP-DOXORUBICIN IN MULTIDRUG-RESISTANT K562 TUMOR-CELLS, AS STUDIED BY LASER CONFOCAL MICROSPECTROFLUOROMETRY

      Anticancer research
    84. MASLAK P; HEGEWISCHBECKER S; GODFREY L; ANDREEFF M
      FLOW CYTOMETRIC DETERMINATION OF THE MULTIDRUG-RESISTANT PHENOTYPE INACUTE-LEUKEMIA

      Cytometry
    85. POMMERENKE E; MATTERN J; VOLM M
      MODULATION OF DOXORUBICIN-TOXICITY BY TAMOXIFEN IN MULTIDRUG-RESISTANT TUMOR-CELLS IN-VITRO AND IN-VIVO

      Journal of cancer research and clinical oncology
    86. NOOTER K; SONNEVELD P
      CLINICAL RELEVANCE OF P-GLYCOPROTEIN EXPRESSION IN HEMATOLOGICAL MALIGNANCIES

      Leukemia research
    87. KIWIT JCW; HERTEL A; MATUSCHEK AE
      REVERSAL OF CHEMORESISTANCE IN MALIGNANT GLIOMAS BY CALCIUM-ANTAGONISTS - CORRELATION WITH THE EXPRESSION OF MULTIDRUG-RESISTANT P-GLYCOPROTEIN

      Journal of neurosurgery
    88. EMMER G; GRASSBERGER MA; SCHULZ G; BOESCH D; GAVERIAUX C; LOOR F
      DERIVATIVES OF A NOVEL CYCLOPEPTOLIDE .2. SYNTHESIS, ACTIVITY AGAINSTMULTIDRUG-RESISTANCE IN CHO AND KB CELLS IN-VITRO, AND STRUCTURE-ACTIVITY-RELATIONSHIPS

      Journal of medicinal chemistry
    89. BOKEMEYER C; DUNN T; HARSTRICK A; LERCH T; POLIWODA H; SCHMOLL HJ
      MODULATION OF CYTOSTATIC DRUGS BY NIFEDIPINE IN 2 HETEROTRANSPLANTED HUMAN TESTICULAR-CANCER CELL-LINES DIFFERING IN THEIR SENSITIVITY TO STANDARD AGENTS

      International journal of cancer
    90. BORREL MN; FIALLO M; PRIEBE W; GARNIERSUILLEROT A
      P-GLYCOPROTEIN-MEDIATED EFFLUX OF HYDROXYRUBICIN, A NEUTRAL ANTHRACYCLINE DERIVATIVE, IN RESISTANT K562 CELLS

      FEBS letters
    91. GRUOL DJ; ZEE MC; TROTTER J; BOURGEOIS S
      REVERSAL OF MULTIDRUG-RESISTANCE BY RU-486

      Cancer research
    92. OUMHAMED Z; BERLION M; MILLOTBROGLIO C; DUFER J; JOLY P; BIZZARI JP; DESPLACES A
      QUANTITATIVE CYTOLOGICAL STUDY OF THE ACT IVITY OF A NEW RESISTANCE MODULATOR, S-9788, ON HUMAN LEUKEMIC-CELLS USING MULTIPARAMETRIC IMAGE-ANALYSIS

      Bulletin du cancer
    93. BIZZARI JP
      PHARMACOLOGICAL PROPERTIES OF S9788, A NE W MULTIDRUG-RESISTANCE MODULATOR

      Bulletin du cancer
    94. MERLIN JL; MARCHAL S; RAMACCI C; LUCAS C; PARAIRE M; POULLAIN MG
      TIME-SCHEDULE DEPENDENT REVERSION OF MULTIDRUG-RESISTANCE BY S9788 INHUMAN TUMOR-CELL LINES

      Bulletin du cancer
    95. SHARP SY; ROWLANDS MG; JARMAN M; KELLAND LR
      EFFECTS OF A NEW ANTIESTROGEN, IDOXIFENE, ON CISPLATIN-SENSITIVE AND DOXORUBICIN-SENSITIVE AND DOXORUBICIN-RESISTANT HUMAN OVARIAN-CARCINOMA CELL-LINES

      British Journal of Cancer
    96. MERLIN JL; GUERCI A; MARCHAL S; MISSOUM N; RAMACCI C; HUMBERT JC; TSURUO T; GUERCI O
      COMPARATIVE-EVALUATION OF S9788, VERAPAMIL, AND CYCLOSPORINE-A IN K562 HUMAN LEUKEMIA-CELL LINES AND IN P-GLYCOPROTEIN-EXPRESSING SAMPLES PATIENTS WITH HEMATOLOGIC MALIGNANCIES

      Blood
    97. KAJIJI S; DRESLIN JA; GRIZZUTI K; GROS P
      STRUCTURALLY DISTINCT MDR MODULATORS SHOW SPECIFIC PATTERNS OF REVERSAL AGAINST P-GLYCOPROTEINS BEARING UNIQUE MUTATIONS AT SERINE(939 941)/

      Biochemistry
    98. HATANO T; OHKAWA K; MATSUDA M
      CYTOTOXIC EFFECT OF THE PROTEIN-DOXORUBICIN CONJUGATES ON THE MULTIDRUG-RESISTANT HUMAN MYELOGENOUS LEUKEMIA-CELL LINE, K562, IN-VITRO

      Tumor biology
    99. PETRINI M; MATTII L; VALENTINI P; SABBATINI ARM; GRASSI B; GRANDI M
      IDARUBICIN IS ACTIVE ON MDR CELLS - EVALUATION OF DNA-SYNTHESIS INHIBITION ON P388 CELL-LINES

      Annals of hematology
    100. NOOTER K; SONNEVELD P
      MULTIDRUG-RESISTANCE (MDR) GENES IN HEMATOLOGICAL MALIGNANCIES

      Cytotechnology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/21 alle ore 23:00:52